ストックスクリーナーアプリを入手
4.4214
0.00%
0.0036
前日終値:
$4.425
開ける：
$4.44
24時間の取引高:
950.26K
Relative Volume:
0.18
時価総額：
$1.06B
収益：
$251.85M
当期純損益:
$-72.58M
株価収益率:
-14.11
EPS:
-0.3134
ネットキャッシュフロー:
$-63.80M
1週間 パフォーマンス:
-3.80%
1か月 パフォーマンス:
+21.90%
6か月 パフォーマンス:
-19.69%
1年 パフォーマンス:
-22.23%
1日の値動き範囲:
$4.27
$4.46
1週間の範囲:
$4.27
$4.69
52週間の値動き範囲:
$3.21
$7.18
Ardelyx Inc Stock (ARDX) Company Profile
ARDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.42 | 1.08B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.47 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.57 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.22 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.19 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.88 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-18 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-02 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | 再開されました | Ladenburg Thalmann | Buy |
| 2025-03-04 | 開始されました | BTIG Research | Buy |
| 2024-11-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-18 | 開始されました | Raymond James | Strong Buy |
| 2023-09-07 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-25 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-11-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | ダウングレード | Jefferies | Buy → Hold |
| 2021-07-20 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-03-23 | 開始されました | Wedbush | Outperform |
| 2021-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-20 | 再開されました | Citigroup | Buy |
| 2020-02-18 | 再開されました | Jefferies | Buy |
| 2020-02-12 | 開始されました | Citigroup | Buy |
| 2020-02-10 | 開始されました | Cowen | Outperform |
| 2019-04-08 | 開始されました | Piper Jaffray | Overweight |
| 2018-08-24 | 開始されました | Jefferies | Buy |
| 2018-03-19 | 再開されました | Leerink Partners | Outperform |
| 2017-11-29 | 繰り返されました | Citigroup | Buy |
| 2017-11-22 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2017-10-17 | 再開されました | Leerink Partners | Outperform |
| 2016-03-31 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-03-09 | 開始されました | Cantor Fitzgerald | Buy |
| 2016-03-03 | 開始されました | Citigroup | Buy |
すべてを表示
Ardelyx Inc (ARDX) 最新ニュース
What drives Ardelyx Inc. stock priceUnstoppable profit momentum - Autocar Professional
Is Ardelyx Inc. a good long term investmentConsistent triple returns - jammulinksnews.com
What analysts say about Ardelyx Inc. stockFree Capital Allocation Plans - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
5 stocks with growth potential: SOUN, JBL, MNTN, ARDX, RCEL - Markets.com
Ardelyx Announces Q2 2025 Financial Results Conference Call - AInvest
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 - The Globe and Mail
Ardelyx Sets Q2 Earnings Date: Key Financial Updates Expected from Biopharma Innovator - Stock Titan
Ardelyx Inc. Stock Analysis and ForecastAccelerated wealth expansion - Autocar Professional
Lobbying Update: $540,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
Wedbush Issues Negative Outlook for Ardelyx Earnings - MarketBeat
This Small-Cap Stock Could 10x By 2030, But It’s Not For The Faint Of Heart - Barchart.com
Wedbush Raises Price Target on Ardelyx to $13 From $11, Keeps Outperform Rating - MarketScreener
Long Term Trading Analysis for (ARDX) - news.stocktradersdaily.com
Jefferies Maintains a Buy Rating on Ardelyx (ARDX) With an $8 Price Target - MSN
Lobbying Update: $50,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
Ardelyx Faces An Uphill Battle Despite Oral Arguments Set In XPHOZAH Appeal (NASDAQ:ARDX) - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on Ardelyx stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Ardelyx stock By Investing.com - Investing.com Nigeria
Ardelyx (ARDX) Appoints New Chief Business and HR Officers - MSN
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT - MSN
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 – ARDX - ACCESS Newswire
Ardelyx amends loan agreement to draw $50 million and secures future options - Investing.com
Ardelyx spike attributed to Xphozah legal update - MSN
Ardelyx stock spike attributed to Xphozah update (ARDX:NASDAQ) - Seeking Alpha
(ARDX) Trading Signals - news.stocktradersdaily.com
A biopharma bolsters patient centricity and trial diversity goals through newly created role - Yahoo Finance
10 Best Healthcare Penny Stocks to Buy According to Analysts - Insider Monkey
Digging for Diamonds in Biotech: Why Insider Buys Signal Opportunity in Nuvation Bio and Ardelyx - AInvest
H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy - MSN
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc.ARDX - PR Newswire
Director David Mott Acquires 200,000 Shares of Ardelyx Inc (ARDX) - GuruFocus
Ardelyx Stockholders Approve Equity Plan Amendment - TipRanks
Ardelyx Inc (ARDX) 財務データ
収益
当期純利益
現金流量
EPS
Ardelyx Inc (ARDX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MOTT DAVID M | Director |
Jun 09 '25 |
Buy |
3.69 |
200,000 |
737,260 |
2,696,871 |
| Williams Laura A | Chief Medical Officer |
May 20 '25 |
Sale |
4.08 |
6,421 |
26,207 |
402,583 |
| Renz Justin A | Chief Financial Officer |
May 20 '25 |
Sale |
4.08 |
7,218 |
29,460 |
416,089 |
| RAAB MICHAEL | President & CEO |
May 20 '25 |
Sale |
4.08 |
46,817 |
191,079 |
1,547,937 |
| Kelliher Mike | See Remarks |
May 20 '25 |
Sale |
4.08 |
14,522 |
59,270 |
282,158 |
| GRAMMER ELIZABETH A | See Remarks |
May 20 '25 |
Sale |
4.08 |
5,992 |
24,456 |
311,731 |
| Foster Eric Duane | Chief Commercial Officer |
May 20 '25 |
Sale |
4.08 |
2,507 |
10,232 |
316,806 |
| MOTT DAVID M | Director |
May 15 '25 |
Buy |
3.29 |
100,000 |
329,120 |
2,496,871 |
| MOTT DAVID M | Director |
May 02 '25 |
Buy |
4.22 |
381,377 |
1,610,936 |
2,396,871 |
| RAAB MICHAEL | President & CEO |
May 02 '25 |
Option Exercise |
0.99 |
20,833 |
20,625 |
1,636,420 |
4.15%
0.51%
大文字化:
|
ボリューム (24 時間):